Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis
The Korean Journal of Internal Medicine
;
: 63-66, 2007.
Article
in English
| WPRIM
| ID: wpr-182817
ABSTRACT
Inhibitors of tumor necrosis factor-alpha (TNF-alpha) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-alpha discontinuation.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Rheumatoid
/
Recombinant Fusion Proteins
/
Immunoglobulin G
/
Adenovirus Infections, Human
/
Risk Factors
/
Immunocompromised Host
/
Receptors, Tumor Necrosis Factor
/
Antirheumatic Agents
/
Antibodies, Monoclonal
Type of study:
Etiology study
/
Risk factors
Limits:
Female
/
Humans
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS